| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 17 | 2021 | 93 | 2.250 |
Why?
|
| Colonic Neoplasms | 30 | 2017 | 556 | 1.960 |
Why?
|
| Adenoma | 9 | 2019 | 235 | 1.720 |
Why?
|
| Adenocarcinoma | 24 | 2019 | 1169 | 1.650 |
Why?
|
| Liver Neoplasms | 14 | 2018 | 735 | 1.620 |
Why?
|
| Liver | 26 | 2018 | 1229 | 1.560 |
Why?
|
| Immunohistochemistry | 37 | 2019 | 1753 | 1.460 |
Why?
|
| Liver Diseases | 8 | 2018 | 238 | 1.440 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2016 | 383 | 1.390 |
Why?
|
| Semantics | 6 | 2015 | 50 | 1.330 |
Why?
|
| Gastric Mucosa | 6 | 2019 | 66 | 1.190 |
Why?
|
| Precancerous Conditions | 11 | 2016 | 196 | 1.130 |
Why?
|
| Colitis | 10 | 2016 | 239 | 1.070 |
Why?
|
| Male | 143 | 2021 | 40956 | 1.030 |
Why?
|
| Brain | 6 | 2016 | 2216 | 1.030 |
Why?
|
| Humans | 192 | 2021 | 86601 | 0.970 |
Why?
|
| Colorectal Neoplasms | 15 | 2019 | 938 | 0.970 |
Why?
|
| Biomarkers, Tumor | 15 | 2019 | 1464 | 0.970 |
Why?
|
| Middle Aged | 95 | 2019 | 25017 | 0.940 |
Why?
|
| Aging | 3 | 2015 | 691 | 0.900 |
Why?
|
| Hepatocytes | 5 | 2010 | 127 | 0.900 |
Why?
|
| Stomach Neoplasms | 6 | 2019 | 266 | 0.890 |
Why?
|
| Cognition Disorders | 5 | 2015 | 236 | 0.870 |
Why?
|
| DNA Mutational Analysis | 6 | 2019 | 526 | 0.870 |
Why?
|
| Esophageal Neoplasms | 12 | 2014 | 321 | 0.870 |
Why?
|
| Memory Disorders | 4 | 2015 | 69 | 0.870 |
Why?
|
| Fatty Liver | 5 | 2013 | 124 | 0.840 |
Why?
|
| Persian Gulf Syndrome | 2 | 2012 | 3 | 0.840 |
Why?
|
| Female | 116 | 2021 | 44507 | 0.840 |
Why?
|
| Aged | 56 | 2019 | 18402 | 0.780 |
Why?
|
| Adult | 73 | 2021 | 25640 | 0.780 |
Why?
|
| Aged, 80 and over | 30 | 2019 | 6501 | 0.740 |
Why?
|
| Colitis, Ulcerative | 11 | 2017 | 711 | 0.740 |
Why?
|
| Inflammatory Bowel Diseases | 6 | 2021 | 549 | 0.730 |
Why?
|
| Liver Cirrhosis | 8 | 2014 | 297 | 0.710 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2014 | 70 | 0.700 |
Why?
|
| Liver Transplantation | 19 | 2017 | 1267 | 0.690 |
Why?
|
| Brain Mapping | 5 | 2016 | 548 | 0.660 |
Why?
|
| Intestinal Mucosa | 14 | 2019 | 797 | 0.640 |
Why?
|
| Immunosuppressive Agents | 11 | 2017 | 977 | 0.640 |
Why?
|
| Diagnosis, Differential | 17 | 2018 | 1565 | 0.630 |
Why?
|
| ErbB Receptors | 9 | 2016 | 485 | 0.630 |
Why?
|
| Evoked Potentials | 2 | 2016 | 190 | 0.620 |
Why?
|
| Chemical and Drug Induced Liver Injury | 5 | 2018 | 69 | 0.590 |
Why?
|
| Biopsy | 20 | 2018 | 1161 | 0.590 |
Why?
|
| Retirement | 2 | 2015 | 10 | 0.590 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 191 | 0.580 |
Why?
|
| Cholangiocarcinoma | 2 | 2014 | 66 | 0.580 |
Why?
|
| Executive Function | 2 | 2015 | 86 | 0.570 |
Why?
|
| Athletes | 2 | 2015 | 46 | 0.570 |
Why?
|
| Archaeology | 1 | 2016 | 14 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 8 | 2016 | 645 | 0.570 |
Why?
|
| Colon | 13 | 2017 | 496 | 0.570 |
Why?
|
| Football | 2 | 2015 | 43 | 0.570 |
Why?
|
| Goblet Cells | 2 | 2014 | 19 | 0.560 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 456 | 0.560 |
Why?
|
| Amnesia | 1 | 2016 | 14 | 0.550 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 24 | 0.550 |
Why?
|
| Crohn Disease | 6 | 2019 | 730 | 0.530 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2014 | 52 | 0.520 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 22 | 0.520 |
Why?
|
| SOX9 Transcription Factor | 1 | 2014 | 23 | 0.510 |
Why?
|
| Colonic Polyps | 3 | 2010 | 126 | 0.510 |
Why?
|
| Cognitive Dysfunction | 2 | 2016 | 132 | 0.500 |
Why?
|
| Visual Perception | 2 | 2015 | 319 | 0.490 |
Why?
|
| Mutation | 10 | 2019 | 3967 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2017 | 1197 | 0.490 |
Why?
|
| West Nile Fever | 1 | 2014 | 21 | 0.490 |
Why?
|
| Azoxymethane | 14 | 2016 | 82 | 0.480 |
Why?
|
| Histoplasmosis | 3 | 2009 | 25 | 0.480 |
Why?
|
| Esophagoscopy | 6 | 2012 | 87 | 0.460 |
Why?
|
| Neuropsychological Tests | 6 | 2016 | 502 | 0.460 |
Why?
|
| Hepatic Veno-Occlusive Disease | 3 | 2012 | 19 | 0.460 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 151 | 0.450 |
Why?
|
| Graft Rejection | 17 | 2014 | 1065 | 0.450 |
Why?
|
| Cadherins | 6 | 2009 | 151 | 0.440 |
Why?
|
| Hemochromatosis | 2 | 2009 | 11 | 0.440 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 26 | 0.440 |
Why?
|
| Reaction Time | 5 | 2016 | 309 | 0.440 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2014 | 427 | 0.440 |
Why?
|
| Biomarkers | 5 | 2017 | 1718 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 11 | 2011 | 1376 | 0.430 |
Why?
|
| Sensitivity and Specificity | 11 | 2016 | 1990 | 0.430 |
Why?
|
| Evoked Potentials, Visual | 1 | 2012 | 87 | 0.420 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 73 | 0.420 |
Why?
|
| Herpesvirus 3, Human | 2 | 2009 | 43 | 0.420 |
Why?
|
| Microdissection | 1 | 2011 | 18 | 0.390 |
Why?
|
| Keratin-7 | 1 | 2010 | 10 | 0.390 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 15 | 0.380 |
Why?
|
| Arginase | 1 | 2010 | 16 | 0.380 |
Why?
|
| Lasers | 1 | 2011 | 106 | 0.380 |
Why?
|
| Gastritis | 3 | 2013 | 32 | 0.380 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2010 | 1 | 0.380 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 26 | 0.380 |
Why?
|
| Cholestasis | 1 | 2010 | 47 | 0.370 |
Why?
|
| Opportunistic Infections | 2 | 2009 | 59 | 0.370 |
Why?
|
| Verbal Learning | 2 | 2007 | 30 | 0.370 |
Why?
|
| Matrix Metalloproteinases | 2 | 2009 | 28 | 0.370 |
Why?
|
| Tranexamic Acid | 1 | 2010 | 25 | 0.370 |
Why?
|
| Toxocariasis | 2 | 2008 | 3 | 0.370 |
Why?
|
| Hemostatics | 1 | 2010 | 56 | 0.370 |
Why?
|
| Hypertension, Portal | 1 | 2010 | 47 | 0.370 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 42 | 0.360 |
Why?
|
| Cytoskeletal Proteins | 5 | 2008 | 223 | 0.360 |
Why?
|
| Cyclin D1 | 7 | 2007 | 83 | 0.360 |
Why?
|
| MicroRNAs | 4 | 2017 | 534 | 0.350 |
Why?
|
| Estradiol | 3 | 2012 | 252 | 0.350 |
Why?
|
| Mental Recall | 2 | 2010 | 159 | 0.350 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 148 | 0.350 |
Why?
|
| Antigens, CD | 3 | 2010 | 458 | 0.340 |
Why?
|
| Depression | 1 | 2013 | 473 | 0.340 |
Why?
|
| Body Fluids | 1 | 2009 | 36 | 0.340 |
Why?
|
| Electrochemistry | 1 | 2009 | 61 | 0.340 |
Why?
|
| Gene Expression Profiling | 6 | 2017 | 1384 | 0.340 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 42 | 0.340 |
Why?
|
| Microelectrodes | 1 | 2009 | 81 | 0.340 |
Why?
|
| Animals | 58 | 2017 | 26581 | 0.340 |
Why?
|
| Immunoglobulin G | 3 | 2013 | 456 | 0.330 |
Why?
|
| Hepatitis C | 5 | 2009 | 208 | 0.330 |
Why?
|
| Immunoassay | 1 | 2009 | 92 | 0.330 |
Why?
|
| Hematoma | 1 | 2009 | 104 | 0.330 |
Why?
|
| Trans-Activators | 5 | 2005 | 429 | 0.330 |
Why?
|
| Bile Duct Neoplasms | 3 | 2014 | 79 | 0.320 |
Why?
|
| Alanine Transaminase | 4 | 2013 | 73 | 0.320 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2020 | 21 | 0.320 |
Why?
|
| Case-Control Studies | 9 | 2017 | 1804 | 0.320 |
Why?
|
| Mice | 39 | 2017 | 11352 | 0.320 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1673 | 0.320 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 68 | 0.320 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 166 | 0.310 |
Why?
|
| Transplantation, Homologous | 14 | 2014 | 996 | 0.310 |
Why?
|
| beta Catenin | 9 | 2016 | 251 | 0.310 |
Why?
|
| Microscopy, Confocal | 4 | 2013 | 268 | 0.310 |
Why?
|
| Intestine, Small | 8 | 2001 | 303 | 0.300 |
Why?
|
| Antibodies, Viral | 1 | 2009 | 293 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2015 | 3352 | 0.300 |
Why?
|
| Genetic Therapy | 1 | 2009 | 342 | 0.300 |
Why?
|
| Language Tests | 1 | 2007 | 37 | 0.300 |
Why?
|
| Down-Regulation | 7 | 2013 | 504 | 0.300 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 683 | 0.290 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 3 | 0.290 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 244 | 0.280 |
Why?
|
| Reproducibility of Results | 9 | 2017 | 2705 | 0.280 |
Why?
|
| Treatment Outcome | 21 | 2017 | 7988 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2013 | 1204 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 146 | 0.270 |
Why?
|
| Disease Progression | 11 | 2012 | 1531 | 0.270 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2019 | 154 | 0.270 |
Why?
|
| Stromal Cells | 3 | 2014 | 143 | 0.270 |
Why?
|
| Plant Extracts | 3 | 2016 | 244 | 0.270 |
Why?
|
| Liver Failure | 2 | 2003 | 78 | 0.260 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2016 | 16 | 0.260 |
Why?
|
| Busulfan | 3 | 2012 | 39 | 0.260 |
Why?
|
| Dementia | 1 | 2007 | 187 | 0.260 |
Why?
|
| United States | 7 | 2015 | 6665 | 0.260 |
Why?
|
| Thioguanine | 1 | 2004 | 17 | 0.250 |
Why?
|
| Staining and Labeling | 3 | 2017 | 165 | 0.250 |
Why?
|
| Observer Variation | 4 | 2021 | 602 | 0.250 |
Why?
|
| Retrospective Studies | 24 | 2019 | 8475 | 0.250 |
Why?
|
| Antiviral Agents | 4 | 2017 | 510 | 0.250 |
Why?
|
| Carcinoma | 4 | 2014 | 436 | 0.250 |
Why?
|
| Caveolins | 1 | 2004 | 2 | 0.250 |
Why?
|
| Renin-Angiotensin System | 2 | 2016 | 133 | 0.250 |
Why?
|
| Thrombospondin 1 | 1 | 2004 | 21 | 0.250 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2016 | 153 | 0.240 |
Why?
|
| Caveolin 1 | 3 | 2017 | 20 | 0.240 |
Why?
|
| Memory | 3 | 2012 | 225 | 0.240 |
Why?
|
| Coronary Artery Bypass | 3 | 2000 | 228 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2007 | 120 | 0.240 |
Why?
|
| Follow-Up Studies | 14 | 2017 | 3636 | 0.240 |
Why?
|
| Young Adult | 12 | 2021 | 5974 | 0.240 |
Why?
|
| Comorbidity | 4 | 2016 | 943 | 0.240 |
Why?
|
| Heart Failure | 2 | 2010 | 1203 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2005 | 68 | 0.230 |
Why?
|
| Asparaginase | 1 | 2003 | 35 | 0.230 |
Why?
|
| Hepatitis, Autoimmune | 5 | 2008 | 19 | 0.230 |
Why?
|
| Osteochondrodysplasias | 1 | 2003 | 11 | 0.230 |
Why?
|
| Brain Concussion | 2 | 2015 | 59 | 0.230 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2012 | 28 | 0.230 |
Why?
|
| Doxycycline | 2 | 2013 | 27 | 0.230 |
Why?
|
| Sigmoid Diseases | 1 | 2003 | 4 | 0.230 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 14 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 108 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 236 | 0.220 |
Why?
|
| Thorax | 1 | 2003 | 75 | 0.220 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2013 | 62 | 0.220 |
Why?
|
| Dilatation, Pathologic | 2 | 2014 | 54 | 0.220 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 470 | 0.220 |
Why?
|
| Histoplasma | 3 | 2009 | 13 | 0.220 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2002 | 1 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 357 | 0.220 |
Why?
|
| Esophagectomy | 4 | 2012 | 84 | 0.220 |
Why?
|
| Collagen | 1 | 2004 | 269 | 0.210 |
Why?
|
| Carcinogenesis | 3 | 2019 | 195 | 0.210 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2016 | 113 | 0.210 |
Why?
|
| Weight Loss | 1 | 2004 | 229 | 0.210 |
Why?
|
| Apoptosis | 7 | 2016 | 1683 | 0.210 |
Why?
|
| Colonoscopy | 4 | 2019 | 264 | 0.210 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2015 | 74 | 0.210 |
Why?
|
| Hepatitis C, Chronic | 2 | 2017 | 126 | 0.210 |
Why?
|
| Tissue Array Analysis | 3 | 2011 | 124 | 0.210 |
Why?
|
| Severity of Illness Index | 8 | 2017 | 1801 | 0.210 |
Why?
|
| Aspartate Aminotransferases | 3 | 2013 | 73 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2005 | 33 | 0.210 |
Why?
|
| Catheter Ablation | 2 | 2016 | 233 | 0.210 |
Why?
|
| Lipodystrophy | 1 | 2001 | 3 | 0.200 |
Why?
|
| ras Proteins | 3 | 2013 | 128 | 0.200 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2001 | 4 | 0.200 |
Why?
|
| Liver Failure, Acute | 2 | 2016 | 38 | 0.200 |
Why?
|
| Gastritis, Hypertrophic | 1 | 2001 | 4 | 0.200 |
Why?
|
| Adenomatous Polyposis Coli Protein | 3 | 2019 | 40 | 0.200 |
Why?
|
| Mesentery | 1 | 2001 | 45 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2014 | 4210 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 2 | 2001 | 144 | 0.190 |
Why?
|
| Peristalsis | 1 | 2000 | 10 | 0.190 |
Why?
|
| Pathologists | 1 | 2021 | 24 | 0.190 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.190 |
Why?
|
| Adolescent | 17 | 2021 | 8979 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2003 | 559 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2010 | 137 | 0.190 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 129 | 0.190 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 140 | 0.190 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2016 | 19 | 0.190 |
Why?
|
| Prognosis | 11 | 2017 | 3674 | 0.190 |
Why?
|
| Electroencephalography | 2 | 2016 | 707 | 0.180 |
Why?
|
| Polyethylene Glycols | 3 | 2008 | 363 | 0.180 |
Why?
|
| Isoenzymes | 4 | 2003 | 271 | 0.180 |
Why?
|
| Cyclooxygenase 2 | 7 | 2009 | 100 | 0.180 |
Why?
|
| Intestinal Obstruction | 1 | 2000 | 88 | 0.180 |
Why?
|
| Blotting, Western | 8 | 2011 | 782 | 0.180 |
Why?
|
| CpG Islands | 2 | 2010 | 151 | 0.180 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1135 | 0.180 |
Why?
|
| RNA, Messenger | 9 | 2011 | 1981 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2000 | 135 | 0.180 |
Why?
|
| Rats | 17 | 2012 | 3990 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2017 | 118 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 17 | 2012 | 3092 | 0.170 |
Why?
|
| Phenotype | 2 | 2019 | 2377 | 0.170 |
Why?
|
| Autoantibodies | 3 | 2014 | 267 | 0.170 |
Why?
|
| Reference Values | 4 | 2013 | 674 | 0.170 |
Why?
|
| Epithelial Cells | 7 | 2016 | 669 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2003 | 23 | 0.170 |
Why?
|
| Risk Factors | 10 | 2016 | 5416 | 0.170 |
Why?
|
| Child | 13 | 2021 | 6926 | 0.170 |
Why?
|
| CDX2 Transcription Factor | 2 | 2016 | 7 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 645 | 0.170 |
Why?
|
| Transcription Factors | 6 | 2014 | 1565 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2003 | 425 | 0.170 |
Why?
|
| Biopsy, Needle | 8 | 2009 | 235 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2016 | 23 | 0.160 |
Why?
|
| Proteins | 2 | 2005 | 777 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 353 | 0.160 |
Why?
|
| Dextran Sulfate | 4 | 2012 | 68 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 157 | 0.160 |
Why?
|
| Neoplasm Staging | 6 | 2011 | 1937 | 0.160 |
Why?
|
| Rats, Inbred F344 | 10 | 2008 | 156 | 0.160 |
Why?
|
| Rectal Neoplasms | 2 | 2012 | 116 | 0.160 |
Why?
|
| Risk Assessment | 7 | 2010 | 2261 | 0.160 |
Why?
|
| Signal Transduction | 11 | 2017 | 3241 | 0.160 |
Why?
|
| Fatal Outcome | 4 | 2009 | 293 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 746 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 532 | 0.160 |
Why?
|
| Disease Models, Animal | 11 | 2016 | 2232 | 0.160 |
Why?
|
| Thrombospondins | 1 | 2017 | 14 | 0.160 |
Why?
|
| Colectomy | 3 | 2016 | 167 | 0.150 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2003 | 37 | 0.150 |
Why?
|
| Sustained Virologic Response | 1 | 2017 | 8 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2015 | 131 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 689 | 0.150 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 35 | 0.150 |
Why?
|
| Collagen Type I | 1 | 2017 | 62 | 0.150 |
Why?
|
| Pathology | 1 | 2017 | 30 | 0.150 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Trachoma | 1 | 2016 | 1 | 0.150 |
Why?
|
| Trichiasis | 1 | 2016 | 1 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 1313 | 0.150 |
Why?
|
| Membrane Proteins | 5 | 2012 | 1196 | 0.150 |
Why?
|
| Focal Adhesions | 1 | 2017 | 69 | 0.150 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 9 | 0.150 |
Why?
|
| Transplantation, Isogeneic | 5 | 1999 | 39 | 0.150 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.150 |
Why?
|
| Esophagus | 1 | 2017 | 102 | 0.140 |
Why?
|
| Fructose | 1 | 2016 | 35 | 0.140 |
Why?
|
| Esophagitis | 2 | 2013 | 42 | 0.140 |
Why?
|
| Analysis of Variance | 5 | 2012 | 912 | 0.140 |
Why?
|
| Endoscopy, Digestive System | 2 | 2013 | 65 | 0.140 |
Why?
|
| Recurrence | 3 | 2016 | 1139 | 0.140 |
Why?
|
| Ontario | 1 | 2016 | 52 | 0.140 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2016 | 7 | 0.140 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 19 | 0.140 |
Why?
|
| Allografts | 1 | 2017 | 172 | 0.140 |
Why?
|
| Population Groups | 1 | 2016 | 41 | 0.140 |
Why?
|
| Behavior, Animal | 3 | 2005 | 373 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 44 | 0.140 |
Why?
|
| HLA Antigens | 2 | 2014 | 232 | 0.140 |
Why?
|
| Emigration and Immigration | 1 | 2016 | 48 | 0.140 |
Why?
|
| Renin | 1 | 2016 | 79 | 0.140 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2008 | 29 | 0.140 |
Why?
|
| Pancreatitis | 2 | 2013 | 87 | 0.140 |
Why?
|
| Photic Stimulation | 3 | 2012 | 493 | 0.140 |
Why?
|
| Cognition | 2 | 2010 | 570 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 121 | 0.140 |
Why?
|
| Mice, Knockout | 11 | 2014 | 1924 | 0.140 |
Why?
|
| Time Factors | 15 | 2013 | 5209 | 0.140 |
Why?
|
| Infant | 9 | 2016 | 3045 | 0.140 |
Why?
|
| Eosinophilia | 2 | 2010 | 84 | 0.140 |
Why?
|
| Intestines | 5 | 2004 | 411 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2014 | 1961 | 0.140 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 54 | 0.140 |
Why?
|
| Diet | 2 | 2011 | 443 | 0.140 |
Why?
|
| Behavior Rating Scale | 1 | 2015 | 6 | 0.140 |
Why?
|
| Transcription Factor AP-1 | 3 | 2008 | 65 | 0.140 |
Why?
|
| Mucins | 3 | 2016 | 39 | 0.130 |
Why?
|
| Living Donors | 3 | 2014 | 339 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2009 | 237 | 0.130 |
Why?
|
| Anticonvulsants | 1 | 2016 | 126 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 1621 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2010 | 628 | 0.130 |
Why?
|
| Hyperplasia | 3 | 2010 | 148 | 0.130 |
Why?
|
| Endoscopy | 2 | 2020 | 332 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1019 | 0.130 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2015 | 16 | 0.130 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2005 | 52 | 0.130 |
Why?
|
| Transaminases | 3 | 2014 | 34 | 0.130 |
Why?
|
| Benzamides | 2 | 2014 | 229 | 0.130 |
Why?
|
| Cholecalciferol | 2 | 2007 | 35 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2016 | 212 | 0.130 |
Why?
|
| Lithiasis | 1 | 2014 | 2 | 0.130 |
Why?
|
| Electron Probe Microanalysis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Research Report | 1 | 2015 | 44 | 0.130 |
Why?
|
| Valine | 1 | 2015 | 69 | 0.130 |
Why?
|
| Vanadium | 1 | 2015 | 13 | 0.130 |
Why?
|
| Cholelithiasis | 1 | 2014 | 34 | 0.130 |
Why?
|
| Pupil | 1 | 2014 | 18 | 0.130 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2014 | 15 | 0.130 |
Why?
|
| Cholangiography | 1 | 2014 | 41 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2016 | 3611 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 348 | 0.130 |
Why?
|
| Acyclovir | 1 | 2015 | 107 | 0.130 |
Why?
|
| Social Environment | 1 | 2016 | 188 | 0.130 |
Why?
|
| Hypertension | 3 | 2001 | 1141 | 0.130 |
Why?
|
| Causality | 1 | 2014 | 81 | 0.130 |
Why?
|
| Syndrome | 3 | 2004 | 446 | 0.130 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2016 | 50 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 33 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 219 | 0.130 |
Why?
|
| Ligands | 4 | 2016 | 433 | 0.130 |
Why?
|
| Neurology | 1 | 2015 | 70 | 0.130 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2012 | 68 | 0.120 |
Why?
|
| West Nile virus | 1 | 2014 | 16 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2013 | 839 | 0.120 |
Why?
|
| Pyrrolidines | 1 | 2014 | 58 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2010 | 229 | 0.120 |
Why?
|
| Autoimmune Diseases | 3 | 2013 | 241 | 0.120 |
Why?
|
| Panax | 2 | 2016 | 170 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 243 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 878 | 0.120 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2010 | 17 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 879 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 223 | 0.120 |
Why?
|
| Cystadenoma | 1 | 2014 | 19 | 0.120 |
Why?
|
| Proteomics | 1 | 2015 | 212 | 0.120 |
Why?
|
| Vidarabine | 2 | 2012 | 141 | 0.120 |
Why?
|
| Graft Survival | 6 | 2007 | 884 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 62 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 188 | 0.120 |
Why?
|
| Mitochondrial Proteins | 2 | 2012 | 123 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2011 | 62 | 0.120 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 462 | 0.120 |
Why?
|
| Microvessels | 2 | 2012 | 70 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2014 | 460 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 425 | 0.110 |
Why?
|
| Hepatitis E | 1 | 2013 | 9 | 0.110 |
Why?
|
| Tight Junctions | 2 | 2012 | 149 | 0.110 |
Why?
|
| Bilirubin | 2 | 2010 | 125 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 154 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2011 | 63 | 0.110 |
Why?
|
| Enteritis | 1 | 2013 | 21 | 0.110 |
Why?
|
| Texas | 1 | 2013 | 101 | 0.110 |
Why?
|
| Carcinogens | 5 | 2007 | 108 | 0.110 |
Why?
|
| Isoantibodies | 1 | 2014 | 114 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 166 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 466 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2014 | 596 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 199 | 0.110 |
Why?
|
| United Kingdom | 2 | 2010 | 164 | 0.110 |
Why?
|
| Azathioprine | 2 | 2013 | 125 | 0.110 |
Why?
|
| Mitochondria, Liver | 1 | 2012 | 27 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 25 | 0.110 |
Why?
|
| Up-Regulation | 5 | 2013 | 712 | 0.110 |
Why?
|
| CD8 Antigens | 4 | 1999 | 82 | 0.110 |
Why?
|
| Rectal Diseases | 1 | 2012 | 24 | 0.100 |
Why?
|
| Contrast Media | 2 | 2015 | 1077 | 0.100 |
Why?
|
| Veterans | 1 | 2012 | 72 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2013 | 113 | 0.100 |
Why?
|
| Histocytochemistry | 3 | 2017 | 130 | 0.100 |
Why?
|
| Fluoxetine | 1 | 2012 | 42 | 0.100 |
Why?
|
| Peptide Hormones | 1 | 2012 | 29 | 0.100 |
Why?
|
| Hamartoma | 1 | 2012 | 31 | 0.100 |
Why?
|
| Genes, ras | 4 | 2007 | 96 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 86 | 0.100 |
Why?
|
| Fear | 1 | 2012 | 78 | 0.100 |
Why?
|
| Hippocampus | 1 | 2015 | 442 | 0.100 |
Why?
|
| Pancreatic Cyst | 1 | 2011 | 28 | 0.100 |
Why?
|
| Family Practice | 3 | 1993 | 84 | 0.100 |
Why?
|
| Bile | 1 | 2011 | 57 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.100 |
Why?
|
| Microtomy | 1 | 2011 | 10 | 0.100 |
Why?
|
| Point Mutation | 2 | 2009 | 246 | 0.100 |
Why?
|
| Chicago | 2 | 2014 | 1379 | 0.100 |
Why?
|
| CD40 Antigens | 2 | 2001 | 43 | 0.100 |
Why?
|
| Caudate Nucleus | 1 | 2010 | 16 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 106 | 0.100 |
Why?
|
| Rabbits | 2 | 2009 | 636 | 0.100 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2011 | 39 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2011 | 135 | 0.100 |
Why?
|
| Cysts | 1 | 2012 | 104 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 196 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 36 | 0.100 |
Why?
|
| Giant Cells | 1 | 2010 | 19 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2270 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 536 | 0.100 |
Why?
|
| Compression Bandages | 1 | 2010 | 7 | 0.100 |
Why?
|
| Receptor, EphB2 | 1 | 2010 | 3 | 0.100 |
Why?
|
| Remission Induction | 4 | 2019 | 722 | 0.100 |
Why?
|
| Hepatitis | 1 | 2010 | 35 | 0.100 |
Why?
|
| Acute Disease | 4 | 2008 | 826 | 0.100 |
Why?
|
| Postoperative Complications | 7 | 2009 | 2207 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2426 | 0.090 |
Why?
|
| Brazil | 1 | 2010 | 69 | 0.090 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 132 | 0.090 |
Why?
|
| Mucin-6 | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 84 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2012 | 1458 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2013 | 352 | 0.090 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2009 | 11 | 0.090 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2010 | 44 | 0.090 |
Why?
|
| Liver Function Tests | 5 | 2013 | 93 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2009 | 17 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 74 | 0.090 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 43 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 5 | 2008 | 552 | 0.090 |
Why?
|
| Integrin beta3 | 1 | 2010 | 30 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2007 | 79 | 0.090 |
Why?
|
| Endosonography | 2 | 2013 | 96 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 158 | 0.090 |
Why?
|
| Abdominal Pain | 2 | 2013 | 137 | 0.090 |
Why?
|
| Age Factors | 2 | 2014 | 1849 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 1075 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 93 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2009 | 78 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 158 | 0.090 |
Why?
|
| Dependovirus | 1 | 2009 | 33 | 0.090 |
Why?
|
| Adenoma, Liver Cell | 1 | 2009 | 2 | 0.090 |
Why?
|
| HCT116 Cells | 3 | 2017 | 151 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 100 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 203 | 0.090 |
Why?
|
| Stomach | 1 | 2010 | 108 | 0.090 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2009 | 25 | 0.090 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 38 | 0.090 |
Why?
|
| Thalamus | 1 | 2010 | 132 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2010 | 48 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 267 | 0.090 |
Why?
|
| Freezing | 1 | 2009 | 33 | 0.090 |
Why?
|
| Caco-2 Cells | 3 | 2012 | 123 | 0.090 |
Why?
|
| Base Sequence | 6 | 2008 | 2330 | 0.090 |
Why?
|
| Inflammation | 2 | 2012 | 920 | 0.080 |
Why?
|
| Physicians | 2 | 2015 | 673 | 0.080 |
Why?
|
| Visual Cortex | 1 | 2012 | 251 | 0.080 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2008 | 5 | 0.080 |
Why?
|
| Urine | 1 | 2009 | 90 | 0.080 |
Why?
|
| Protein Stability | 1 | 2009 | 99 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 90 | 0.080 |
Why?
|
| DNA Primers | 3 | 2008 | 543 | 0.080 |
Why?
|
| Sphingomonadaceae | 1 | 2008 | 2 | 0.080 |
Why?
|
| Space Perception | 1 | 1990 | 115 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2009 | 201 | 0.080 |
Why?
|
| Transcriptome | 1 | 2013 | 580 | 0.080 |
Why?
|
| Iron | 1 | 2009 | 164 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 190 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2008 | 94 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2008 | 2 | 0.080 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2008 | 12 | 0.080 |
Why?
|
| Mass Screening | 1 | 1993 | 617 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 23 | 0.080 |
Why?
|
| Viral Envelope Proteins | 1 | 2008 | 94 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 373 | 0.080 |
Why?
|
| Triglycerides | 1 | 2009 | 232 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 621 | 0.080 |
Why?
|
| Cause of Death | 1 | 2009 | 277 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 183 | 0.080 |
Why?
|
| Indomethacin | 1 | 2008 | 59 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 894 | 0.080 |
Why?
|
| Cats | 1 | 2008 | 303 | 0.080 |
Why?
|
| Mastocytosis | 1 | 2007 | 13 | 0.080 |
Why?
|
| Knee Prosthesis | 1 | 2008 | 33 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 133 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1685 | 0.080 |
Why?
|
| Mucin-1 | 2 | 2012 | 44 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2008 | 233 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2009 | 439 | 0.080 |
Why?
|
| Amyloidosis | 1 | 2009 | 115 | 0.080 |
Why?
|
| Equipment Design | 1 | 2009 | 406 | 0.080 |
Why?
|
| Cholangitis | 1 | 2007 | 19 | 0.080 |
Why?
|
| Regeneration | 1 | 2008 | 143 | 0.080 |
Why?
|
| Temperature | 1 | 2009 | 396 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1578 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2010 | 492 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2008 | 2600 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2008 | 159 | 0.080 |
Why?
|
| Immediate-Early Proteins | 1 | 2008 | 164 | 0.080 |
Why?
|
| Hepatic Encephalopathy | 2 | 1999 | 40 | 0.080 |
Why?
|
| Genes, p53 | 1 | 2007 | 109 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.070 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 43 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 134 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 111 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 329 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 303 | 0.070 |
Why?
|
| Carcinoembryonic Antigen | 3 | 1994 | 41 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 356 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 2006 | 18 | 0.070 |
Why?
|
| Fever | 2 | 2005 | 125 | 0.070 |
Why?
|
| Choledocholithiasis | 1 | 2006 | 12 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 267 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 17 | 0.070 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 819 | 0.070 |
Why?
|
| Glycogen | 1 | 2006 | 59 | 0.070 |
Why?
|
| Tacrolimus | 5 | 2003 | 373 | 0.070 |
Why?
|
| Frontal Lobe | 1 | 2007 | 130 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 352 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2006 | 24 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 272 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2008 | 111 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2006 | 326 | 0.070 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2005 | 5 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 1576 | 0.070 |
Why?
|
| Receptors, Kainic Acid | 1 | 2005 | 13 | 0.070 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2005 | 4 | 0.070 |
Why?
|
| Cell Division | 6 | 2007 | 696 | 0.070 |
Why?
|
| Suction | 1 | 2005 | 35 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2009 | 544 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2009 | 1373 | 0.070 |
Why?
|
| Oxygen | 1 | 2010 | 726 | 0.070 |
Why?
|
| Ploidies | 2 | 1996 | 40 | 0.070 |
Why?
|
| Prodrugs | 1 | 2005 | 46 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2005 | 46 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 397 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 381 | 0.070 |
Why?
|
| Snail Family Transcription Factors | 3 | 2014 | 26 | 0.070 |
Why?
|
| Adenoma, Villous | 1 | 2005 | 2 | 0.070 |
Why?
|
| Angiotensin II | 2 | 2016 | 94 | 0.070 |
Why?
|
| Butanones | 1 | 2005 | 6 | 0.070 |
Why?
|
| Vitamin D | 1 | 2007 | 261 | 0.070 |
Why?
|
| Alcoholism | 2 | 2014 | 172 | 0.070 |
Why?
|
| Conditioning, Operant | 2 | 1999 | 73 | 0.060 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sodium | 1 | 1986 | 341 | 0.060 |
Why?
|
| Cimicifuga | 1 | 2004 | 3 | 0.060 |
Why?
|
| CD40 Ligand | 2 | 2003 | 69 | 0.060 |
Why?
|
| Genes, APC | 1 | 2004 | 26 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 1985 | 121 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 144 | 0.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2004 | 28 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 59 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2005 | 162 | 0.060 |
Why?
|
| Mucous Membrane | 3 | 2009 | 83 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2004 | 54 | 0.060 |
Why?
|
| Gastric Fundus | 1 | 2004 | 7 | 0.060 |
Why?
|
| Gene Expression | 3 | 2009 | 1284 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 56 | 0.060 |
Why?
|
| Protein Kinase C | 2 | 2012 | 270 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 50 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2017 | 327 | 0.060 |
Why?
|
| Polyps | 1 | 2004 | 28 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2004 | 579 | 0.060 |
Why?
|
| Necrosis | 4 | 2013 | 204 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 302 | 0.060 |
Why?
|
| Asphyxia | 1 | 2003 | 10 | 0.060 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2003 | 11 | 0.060 |
Why?
|
| Prevalence | 3 | 2016 | 1239 | 0.060 |
Why?
|
| CD28 Antigens | 2 | 2003 | 88 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2004 | 133 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 88 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2003 | 32 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2005 | 394 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 927 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2002 | 10 | 0.060 |
Why?
|
| Immunoconjugates | 2 | 2003 | 106 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2015 | 2767 | 0.060 |
Why?
|
| Metaplasia | 2 | 2016 | 37 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 106 | 0.060 |
Why?
|
| Surgical Instruments | 2 | 1999 | 57 | 0.050 |
Why?
|
| Liver Glycogen | 1 | 2002 | 5 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 286 | 0.050 |
Why?
|
| Neoplasms | 3 | 2017 | 2897 | 0.050 |
Why?
|
| Chlamydophila Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Constipation | 1 | 2003 | 63 | 0.050 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2002 | 12 | 0.050 |
Why?
|
| Paget's Disease, Mammary | 1 | 2001 | 3 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 16 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2001 | 8 | 0.050 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 10 | 0.050 |
Why?
|
| Primary Health Care | 1 | 1985 | 339 | 0.050 |
Why?
|
| Ileum | 2 | 2019 | 159 | 0.050 |
Why?
|
| Mucin-2 | 3 | 2012 | 12 | 0.050 |
Why?
|
| Mice, Inbred C3H | 5 | 2001 | 370 | 0.050 |
Why?
|
| Piperazines | 1 | 2003 | 272 | 0.050 |
Why?
|
| Enalapril | 1 | 2001 | 18 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2002 | 29 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 1056 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2014 | 1219 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 1208 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2012 | 930 | 0.050 |
Why?
|
| Transplantation Chimera | 2 | 2003 | 80 | 0.050 |
Why?
|
| Alemtuzumab | 2 | 2012 | 83 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2001 | 27 | 0.050 |
Why?
|
| Mice, Inbred Strains | 4 | 2008 | 307 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 2 | 2006 | 70 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2001 | 23 | 0.050 |
Why?
|
| Probability | 3 | 2009 | 355 | 0.050 |
Why?
|
| Calcitriol | 2 | 2007 | 174 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 273 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 158 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2008 | 1538 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1185 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2003 | 370 | 0.050 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 728 | 0.050 |
Why?
|
| Heat Stroke | 1 | 2000 | 9 | 0.050 |
Why?
|
| Chromans | 1 | 2000 | 30 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2001 | 107 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2012 | 334 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 74 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 122 | 0.050 |
Why?
|
| Injections | 1 | 2020 | 109 | 0.050 |
Why?
|
| Fatty Acids | 2 | 2012 | 130 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2013 | 265 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 999 | 0.050 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 78 | 0.050 |
Why?
|
| Surgical Equipment | 1 | 1999 | 5 | 0.050 |
Why?
|
| Mentors | 1 | 2021 | 76 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2000 | 82 | 0.040 |
Why?
|
| Transfection | 3 | 2012 | 896 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 280 | 0.040 |
Why?
|
| Microtubules | 1 | 2000 | 119 | 0.040 |
Why?
|
| Avoidance Learning | 1 | 1999 | 16 | 0.040 |
Why?
|
| Muscarinic Agonists | 1 | 1999 | 23 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2012 | 66 | 0.040 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1999 | 118 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 75 | 0.040 |
Why?
|
| Dopamine Antagonists | 1 | 1999 | 35 | 0.040 |
Why?
|
| Thiazoles | 1 | 2000 | 131 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2003 | 375 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 222 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2011 | 970 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.040 |
Why?
|
| Linear Models | 2 | 2010 | 421 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2014 | 1195 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 78 | 0.040 |
Why?
|
| Illinois | 2 | 2010 | 462 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 123 | 0.040 |
Why?
|
| Coronary Disease | 1 | 1999 | 261 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2501 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 382 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 451 | 0.040 |
Why?
|
| Ascariasis | 1 | 1977 | 2 | 0.040 |
Why?
|
| Mice, Inbred A | 2 | 2007 | 23 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 1996 | 265 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1998 | 120 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 100 | 0.040 |
Why?
|
| Liver Abscess | 1 | 1997 | 12 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2000 | 378 | 0.040 |
Why?
|
| Zingiberaceae | 1 | 2016 | 9 | 0.040 |
Why?
|
| Zanthoxylum | 1 | 2016 | 9 | 0.040 |
Why?
|
| Candidiasis | 1 | 1997 | 36 | 0.040 |
Why?
|
| Medicine, Traditional | 1 | 2016 | 8 | 0.040 |
Why?
|
| Gambia | 1 | 2016 | 2 | 0.040 |
Why?
|
| Insulin Resistance | 2 | 2009 | 377 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 125 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 51 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2007 | 3030 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 376 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2016 | 10 | 0.040 |
Why?
|
| Allopurinol | 1 | 2017 | 80 | 0.040 |
Why?
|
| Gout Suppressants | 1 | 2017 | 36 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2818 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.040 |
Why?
|
| Hydralazine | 1 | 2016 | 20 | 0.040 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 4 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1823 | 0.040 |
Why?
|
| Blindness | 1 | 2016 | 41 | 0.040 |
Why?
|
| Spiro Compounds | 1 | 2016 | 25 | 0.040 |
Why?
|
| Fumarates | 1 | 2016 | 26 | 0.040 |
Why?
|
| Losartan | 1 | 2016 | 42 | 0.040 |
Why?
|
| Diet, Western | 1 | 2016 | 37 | 0.040 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2016 | 15 | 0.040 |
Why?
|
| Amides | 1 | 2016 | 60 | 0.040 |
Why?
|
| Cell Line | 4 | 2008 | 2468 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 696 | 0.040 |
Why?
|
| Gout | 1 | 2017 | 76 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 81 | 0.030 |
Why?
|
| Quinazolines | 2 | 2008 | 220 | 0.030 |
Why?
|
| Diclofenac | 1 | 1995 | 4 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 2016 | 90 | 0.030 |
Why?
|
| Genotype | 2 | 2013 | 1850 | 0.030 |
Why?
|
| Retinal Diseases | 1 | 1977 | 90 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 114 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 269 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 136 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 864 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 80 | 0.030 |
Why?
|
| Mice, Inbred DBA | 2 | 2005 | 148 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 90 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 458 | 0.030 |
Why?
|
| Fibrosis | 2 | 2010 | 203 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1995 | 22 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 112 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 63 | 0.030 |
Why?
|
| Body Temperature | 2 | 2005 | 124 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 65 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 91 | 0.030 |
Why?
|
| Masoprocol | 1 | 1995 | 3 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 1995 | 34 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 1995 | 35 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2009 | 873 | 0.030 |
Why?
|
| RNA Interference | 2 | 2007 | 369 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2016 | 186 | 0.030 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 95 | 0.030 |
Why?
|
| Heart Transplantation | 2 | 1999 | 705 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 1995 | 42 | 0.030 |
Why?
|
| Mydriasis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2006 | 303 | 0.030 |
Why?
|
| Miosis | 1 | 2014 | 10 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2007 | 2062 | 0.030 |
Why?
|
| Splenectomy | 1 | 2014 | 82 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 181 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 288 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1975 | 105 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 454 | 0.030 |
Why?
|
| Flow Cytometry | 4 | 2003 | 679 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 1054 | 0.030 |
Why?
|
| Fentanyl | 1 | 2014 | 65 | 0.030 |
Why?
|
| Gadolinium | 1 | 2015 | 103 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 364 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 481 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2004 | 159 | 0.030 |
Why?
|
| Histocompatibility Testing | 2 | 2014 | 154 | 0.030 |
Why?
|
| Caspases | 2 | 2004 | 155 | 0.030 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2014 | 98 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 69 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 391 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 129 | 0.030 |
Why?
|
| Random Allocation | 2 | 2002 | 332 | 0.030 |
Why?
|
| Complement C4b | 1 | 2014 | 35 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 23 | 0.030 |
Why?
|
| Spouses | 1 | 2014 | 33 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 541 | 0.030 |
Why?
|
| Stress, Physiological | 2 | 2005 | 226 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 678 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2014 | 148 | 0.030 |
Why?
|
| Morphine | 1 | 2014 | 130 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 399 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 744 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 66 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2006 | 153 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 2013 | 6 | 0.030 |
Why?
|
| Wales | 1 | 1993 | 10 | 0.030 |
Why?
|
| Roseolovirus Infections | 1 | 2013 | 7 | 0.030 |
Why?
|
| Naltrexone | 1 | 2014 | 135 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2013 | 19 | 0.030 |
Why?
|
| Ganciclovir | 1 | 2013 | 49 | 0.030 |
Why?
|
| Survival Rate | 3 | 2007 | 1860 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 167 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 329 | 0.030 |
Why?
|
| Capillaries | 1 | 2013 | 91 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 14 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2012 | 22 | 0.030 |
Why?
|
| Epilepsy | 1 | 2016 | 395 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Influenza, Human | 1 | 1975 | 329 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2013 | 393 | 0.030 |
Why?
|
| Bile Ducts | 2 | 2003 | 59 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2012 | 32 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2012 | 80 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2012 | 164 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2013 | 112 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 33 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 384 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 2357 | 0.030 |
Why?
|
| Fluorescein | 1 | 2011 | 16 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2013 | 476 | 0.030 |
Why?
|
| Facial Expression | 1 | 2012 | 51 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 64 | 0.030 |
Why?
|
| Abatacept | 2 | 2003 | 83 | 0.030 |
Why?
|
| Fasting | 1 | 2012 | 161 | 0.030 |
Why?
|
| Mucin 5AC | 2 | 2001 | 8 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 111 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 101 | 0.030 |
Why?
|
| Tissue Donors | 2 | 1994 | 463 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 239 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 63 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2002 | 102 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 37 | 0.020 |
Why?
|
| Health Promotion | 1 | 1993 | 160 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 373 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 554 | 0.020 |
Why?
|
| Fats | 1 | 2010 | 12 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 363 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 314 | 0.020 |
Why?
|
| Reoperation | 3 | 1999 | 597 | 0.020 |
Why?
|
| Alagille Syndrome | 1 | 2010 | 5 | 0.020 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 113 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 639 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 752 | 0.020 |
Why?
|
| Hypopituitarism | 1 | 2010 | 19 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 256 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 179 | 0.020 |
Why?
|
| Biliary Atresia | 1 | 2010 | 22 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 121 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 183 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 307 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Problem Solving | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2010 | 68 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 674 | 0.020 |
Why?
|
| Skin Transplantation | 2 | 2003 | 172 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 224 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 1990 | 18 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 444 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 238 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 211 | 0.020 |
Why?
|
| Models, Biological | 2 | 2012 | 1749 | 0.020 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2009 | 25 | 0.020 |
Why?
|
| Shellfish | 1 | 1969 | 5 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2009 | 7 | 0.020 |
Why?
|
| Guatemala | 1 | 2009 | 4 | 0.020 |
Why?
|
| Antibodies, Fungal | 1 | 2009 | 7 | 0.020 |
Why?
|
| Hepatitis A | 1 | 1969 | 4 | 0.020 |
Why?
|
| Jejunum | 2 | 2001 | 79 | 0.020 |
Why?
|
| Time | 1 | 2009 | 77 | 0.020 |
Why?
|
| Papio | 1 | 2009 | 82 | 0.020 |
Why?
|
| Cyclosporine | 2 | 2003 | 234 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 44 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1106 | 0.020 |
Why?
|
| Amyloid | 1 | 2009 | 85 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 638 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 724 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 229 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 307 | 0.020 |
Why?
|
| Keloid | 1 | 2008 | 8 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 261 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1034 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2008 | 15 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 444 | 0.020 |
Why?
|
| Endometrium | 1 | 2008 | 48 | 0.020 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 332 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 14 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2008 | 12 | 0.020 |
Why?
|
| Ribavirin | 1 | 2008 | 57 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 134 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 1041 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 29 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 279 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 35 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 82 | 0.020 |
Why?
|
| Osteoarthritis, Hip | 1 | 2008 | 23 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2008 | 80 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 339 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 78 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 2887 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 148 | 0.020 |
Why?
|
| Bacteria | 1 | 2011 | 447 | 0.020 |
Why?
|
| Ulcer | 1 | 2007 | 36 | 0.020 |
Why?
|
| Bacteriophage lambda | 1 | 1987 | 24 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1989 | 142 | 0.020 |
Why?
|
| Permeability | 1 | 2007 | 137 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2007 | 45 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2008 | 154 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 114 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2007 | 104 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2008 | 166 | 0.020 |
Why?
|
| Kinetics | 2 | 2000 | 1513 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 663 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 101 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 33 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 963 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 1156 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1583 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 115 | 0.020 |
Why?
|
| Knee Joint | 1 | 2008 | 168 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2006 | 9 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 347 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 351 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 379 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2006 | 34 | 0.020 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1986 | 14 | 0.020 |
Why?
|
| Muromonab-CD3 | 2 | 1996 | 69 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 192 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 12 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 32 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1014 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 83 | 0.020 |
Why?
|
| Light | 1 | 2007 | 289 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 249 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 42 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 547 | 0.020 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 281 | 0.020 |
Why?
|
| Biological Availability | 1 | 2005 | 92 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2005 | 49 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 350 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2005 | 36 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.020 |
Why?
|
| Alanine | 1 | 2005 | 85 | 0.020 |
Why?
|
| GATA6 Transcription Factor | 1 | 2005 | 13 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2005 | 74 | 0.020 |
Why?
|
| Wound Healing | 1 | 2007 | 344 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 19 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2007 | 459 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 853 | 0.020 |
Why?
|
| DNA | 2 | 1989 | 1294 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 80 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2004 | 18 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2004 | 11 | 0.020 |
Why?
|
| Morpholinos | 1 | 2004 | 13 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 121 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 78 | 0.020 |
Why?
|
| Drug Resistance | 2 | 1996 | 256 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2010 | 2378 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 339 | 0.020 |
Why?
|
| Multigene Family | 1 | 2005 | 202 | 0.020 |
Why?
|
| Morpholines | 1 | 2004 | 65 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 369 | 0.020 |
Why?
|
| Insulin | 1 | 2009 | 1160 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 229 | 0.020 |
Why?
|
| Peptides | 1 | 2007 | 639 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2004 | 54 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 503 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2005 | 684 | 0.010 |
Why?
|
| Cell Movement | 1 | 2007 | 758 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 66 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 128 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 66 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 74 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2003 | 15 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 126 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1720 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 317 | 0.010 |
Why?
|
| Transplantation | 1 | 2003 | 39 | 0.010 |
Why?
|
| Mitosis | 1 | 2003 | 153 | 0.010 |
Why?
|
| Motor Activity | 1 | 2005 | 327 | 0.010 |
Why?
|
| Water | 1 | 2004 | 275 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 268 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 356 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 149 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1989 | 1920 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 91 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 2002 | 41 | 0.010 |
Why?
|
| Vulva | 1 | 2001 | 23 | 0.010 |
Why?
|
| Scrotum | 1 | 2001 | 17 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 430 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 129 | 0.010 |
Why?
|
| African Americans | 1 | 2001 | 10 | 0.010 |
Why?
|
| Peptide Library | 1 | 2002 | 84 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 81 | 0.010 |
Why?
|
| Nipples | 1 | 2001 | 36 | 0.010 |
Why?
|
| Penis | 1 | 2001 | 57 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 255 | 0.010 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Urothelium | 1 | 2001 | 70 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 16 | 0.010 |
Why?
|
| Cadaver | 1 | 2001 | 185 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 557 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 258 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1047 | 0.010 |
Why?
|
| Anal Canal | 1 | 2001 | 89 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 88 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 69 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 589 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 137 | 0.010 |
Why?
|
| Arthritis | 1 | 2001 | 46 | 0.010 |
Why?
|
| Nocodazole | 1 | 2000 | 18 | 0.010 |
Why?
|
| HIV Infections | 1 | 2009 | 772 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 751 | 0.010 |
Why?
|
| Colchicine | 1 | 2000 | 23 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 68 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 182 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2000 | 28 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 177 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 111 | 0.010 |
Why?
|
| Vinblastine | 1 | 2000 | 108 | 0.010 |
Why?
|
| Pilocarpine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1999 | 29 | 0.010 |
Why?
|
| Succinimides | 1 | 1999 | 13 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 22 | 0.010 |
Why?
|
| Diazepam | 1 | 1999 | 27 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1999 | 31 | 0.010 |
Why?
|
| Haloperidol | 1 | 1999 | 30 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 1999 | 49 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2001 | 325 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1999 | 83 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 1999 | 45 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1999 | 25 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 114 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1999 | 135 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 141 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1999 | 74 | 0.010 |
Why?
|
| Guanine | 1 | 1999 | 208 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1999 | 148 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 171 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1998 | 30 | 0.010 |
Why?
|
| Shock | 1 | 1998 | 42 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1998 | 48 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1999 | 164 | 0.010 |
Why?
|
| Th2 Cells | 1 | 1999 | 146 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1998 | 124 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1998 | 97 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 460 | 0.010 |
Why?
|
| Breast | 1 | 2000 | 286 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1998 | 27 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 1997 | 8 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1998 | 158 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 127 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 937 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2000 | 355 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1997 | 80 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 184 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1977 | 96 | 0.010 |
Why?
|
| Polyploidy | 1 | 1996 | 17 | 0.010 |
Why?
|
| Diploidy | 1 | 1996 | 30 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1977 | 316 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 200 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1996 | 55 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 66 | 0.010 |
Why?
|
| Length of Stay | 1 | 1999 | 700 | 0.010 |
Why?
|
| Visual Acuity | 1 | 1977 | 194 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1995 | 13 | 0.010 |
Why?
|
| Bismuth | 1 | 1995 | 8 | 0.010 |
Why?
|
| Metronidazole | 1 | 1995 | 26 | 0.010 |
Why?
|
| Thrombosis | 1 | 1998 | 296 | 0.010 |
Why?
|
| Work | 1 | 1975 | 16 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1995 | 54 | 0.010 |
Why?
|
| Cytokines | 1 | 1999 | 776 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1975 | 37 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1996 | 233 | 0.010 |
Why?
|
| Schools | 1 | 1975 | 71 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1975 | 105 | 0.010 |
Why?
|
| Medical Records | 1 | 1975 | 119 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 365 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 502 | 0.010 |
Why?
|
| Forecasting | 1 | 1994 | 304 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1961 | 1004 | 0.010 |
Why?
|
| Hospitalization | 1 | 1975 | 848 | 0.010 |
Why?
|
| Connecticut | 1 | 1969 | 27 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1989 | 98 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 1969 | 22 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 245 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1989 | 256 | 0.010 |
Why?
|
| Isoantigens | 1 | 1989 | 66 | 0.010 |
Why?
|
| Geography | 1 | 1969 | 223 | 0.010 |
Why?
|
| Plasmids | 1 | 1989 | 287 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1969 | 154 | 0.010 |
Why?
|
| Introns | 1 | 1989 | 289 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1989 | 646 | 0.000 |
Why?
|
| Seasons | 1 | 1969 | 223 | 0.000 |
Why?
|
| Exons | 1 | 1989 | 450 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1987 | 1074 | 0.000 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1958 | 9 | 0.000 |
Why?
|
| Venae Cavae | 1 | 1958 | 14 | 0.000 |
Why?
|
| Peptic Ulcer | 1 | 1958 | 19 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1969 | 71 | 0.000 |
Why?
|
| Respiratory Function Tests | 1 | 1969 | 136 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1969 | 221 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1969 | 298 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1969 | 478 | 0.000 |
Why?
|
| Myocardium | 1 | 1969 | 529 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1969 | 375 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1969 | 710 | 0.000 |
Why?
|